Please assess the completion status of the following clinical trial:

Trial Title: HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~A participant must meet all of the following criteria:~Completed three injections of 4 mg or 8 mg of study vaccine in VRC 004 (03-I-0022) without experiencing a serious adverse event (SAE) that was possibly, probably or definitely related to study vaccine.~Available for clinical follow-up for 24 weeks after enrollment.~Completion of an Assessment of Understanding prior to enrollment and able to verbalize understanding of all questions answered incorrectly.~Able and willing to complete the informed consent process.~Willing to receive HIV test results and willing to abide by NIH guidelines for partner notification of positive HIV results.~Willing to donate blood for sample storage to be used for future research.~Willing to discuss HIV infection risks and amenable to risk reduction counseling.~In good general health without clinically significant medical history and satisfactory completion of the screening process.~Laboratory Criteria within 28 days prior to enrollment:~Hemoglobin greater than or equal to 11.5 g/dL for women; greater than or equal to 13.5 g/dL for men.~WBC = 3,300-12,000 cells/mm(3).~Differential either within institutional normal range or accompanied by site physician approval.~Total lymphocyte count greater than or equal to 800 cells/mm(3).~Platelets = 125,000 - 550,000/mm(3).~ALT (SGPT) less than or equal to 1.25 x upper limit of normal.~Serum creatinine less than or equal to 1 x upper limit of normal (less than or equal to 1.3 mg/dL for females; less than or equal to 1.4 mg/dL for males).~Normal urinalysis defined as negative glucose, negative or trace protein, and no clinically significant blood in the urine.~Negative HIV PCR.~Negative Hepatitis B surface antigen.~Negative anti-HCV.~Female-Specific Criteria:~Negative beta-HCG pregnancy test (urine) on day of study enrollment for women presumed to be of reproductive potential.~A female participant must meet one of the following criteria:~No reproductive potential because of menopause \[one year without menses\] or because of a hysterectomy, bilateral oophorectomy, or tubal ligation,~or~Participant agrees to be heterosexually inactive at least 21 days prior to enrollment and through Week 24 of the study,~or~Participant agrees to consistently practice contraception at least 21 days prior to enrollment and through Week 24 of the study by one of the following methods:~* condoms, male or female, with or without a spermicide~* diaphragm or cervical cap with spermicide~* intrauterine device~* contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method~* male partner has previously undergone a vasectomy for which there is documentation.~EXCLUSION CRITERIA:~A volunteer will be excluded if one or more of the following conditions apply:~Women:~Breast-feeding or planning to become pregnant during the 24 weeks of study participation.~Volunteer has received any of the following substances:~Immunosuppressive or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis).~Blood products within 120 days prior to HIV screening.~Immunoglobulin within 60 days prior to HIV screening.~Live attenuated vaccines within 30 days prior to initial study vaccine administration.~Investigational research agents within 30 days prior to study vaccine administration.~Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration.~Current anti-TB prophylaxis or therapy.~Volunteer has a history of any of the following clinically significant conditions:~Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain.~Autoimmune disease or immunodeficiency.~Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids.~Diabetes mellitus (type I or II), with the exception of gestational diabetes.~History of thyroidectomy or thyroid disease that required medication within the past 12 months.~Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years.~Hypertension that is not well-controlled by medication or is more than 145/95 at enrollment.~Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~Syphilis infection that is active or a positive serology due to a syphilis infection treated less than six months ago.~Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study.~Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years.~Asplenia or any condition resulting in the absence or removal of the spleen.~Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment.~Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete